Zymeworks, GSK Sign Antibody Deal For Up To $440m
This article was originally published in Scrip
Zymeworks Inc. nabbed its fourth major partner by entering into a collaboration and licensing deal with GlaxoSmithKline PLC for the development of novel Fc-engineered monoclonal and bi-specific antibodies for the treatment of various undisclosed diseases.
You may also be interested in...
Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.